Indian pharma companies to increase their revenues are increasingly relying on positioning themselves in niche or specialty areas. Last year Shreya Life Sciences launched the world''s first oral insulin under the brand name of ''Oral- Recosulin''. The company''s top brass already announced that it is bullish on specialty products.
Significant amount of investments is required for niche or specialty products but within smaller markets the high entry barriers providing an extremely limited competition. However, the Indian biggies too are showing an interest in the niche strategy. The presence of Sun Pharma in chronic therapy areas like psychiatry, cardiology, oncology accounts for over 90 per cent of Indian turnover. In line with this, Orchid Pharma claims 80-85 per cent of the current turnover is contributed by Cephalosporin products in antibiotics. Apart from this, Piramal''s acquisitions last year in inhalation anesthetics cementing presence in the critical care space. Along with this, Lupin has established its presence in the pediatric space through the franchise of its antibiotic Suprax in US.
Significant amount of investments is required for niche or specialty products but within smaller markets the high entry barriers providing an extremely limited competition. However, the Indian biggies too are showing an interest in the niche strategy. The presence of Sun Pharma in chronic therapy areas like psychiatry, cardiology, oncology accounts for over 90 per cent of Indian turnover. In line with this, Orchid Pharma claims 80-85 per cent of the current turnover is contributed by Cephalosporin products in antibiotics. Apart from this, Piramal''s acquisitions last year in inhalation anesthetics cementing presence in the critical care space. Along with this, Lupin has established its presence in the pediatric space through the franchise of its antibiotic Suprax in US.
No comments:
Post a Comment